Company Snapshot: Paratek Pharmaceuticals

PRTK
Last	Change	Volume	High	Low

Company Overview

Paratek Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon its expertise in novel tetracycline chemistry. The company’s lead product candidate, Omadacycline, is a novel investigational antibiotic with both once-daily intravenous (IV) and oral formulations for the treatment of community-acquired bacterial pneumonia (CABP), acute bacterial skin and skin structure infections (ABSSSI), and urinary tract infections (UTI). A modernized tetracycline, omadacycline is specifically designed to overcome tetracycline resistance and exhibits activity across a broad spectrum of bacteria, including Gram-positive, Gram-negative, anaerobes, atypical bacteria, and other drug-resistant strains.

Client News

1. Aug 6 2019 Paratek Pharmaceuticals Generates Net Revenues of $2.0 Million in the Second Quarter of 2019
2. Aug 1 2019 Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
3. Jul 29 2019 Paratek Pharmaceuticals to Report Second Quarter 2019 Financial Results on August 6, 2019
4. Jun 25 2019 Paratek Pharmaceuticals Promotes Evan Loh, M.D. to Chief Executive Officer; Michael Bigham to Assume Role of Executive Chairman
5. May 8 2019 Paratek’s NUZYRA™ (omadacycline) Generates Net Sales of $1.3 Million in the First Eight Weeks on the U.S. Market